Aclaris Therapeutics Announces Leadership Transition

Core Insights - Aclaris Therapeutics, Inc. has appointed Roland Kolbeck, Ph.D. as the new Chief Scientific Officer, succeeding Joe Monahan, Ph.D., who will transition to a Special Scientific Advisor role until March 2026 as part of his planned retirement [1][2] - Dr. Kolbeck brings nearly three decades of experience in R&D leadership and a strong track record in drug development, particularly in immuno-inflammatory diseases [2][3] - The company is focused on developing a pipeline of novel product candidates, including next-generation kinase and cytokine signaling pathway inhibitors and potential first-in-class bispecific antibodies [1][2] Company Overview - Aclaris Therapeutics is a clinical-stage biopharmaceutical company dedicated to addressing the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options [3] - The company has a multi-stage portfolio powered by a robust R&D engine, indicating a strong commitment to innovation and therapeutic development [3]